Type 2 diabetes

Glyscend has presented data during the American Diabetes Association 80th Scientific Sessions virtual meeting, from a study of its proprietary oral polymer duodenal exclusion therapy. The positive data were presented ahead of Glyscend’s Phase I clinical trials, which have commenced recruiting healthy subjects in South Australia. Glyscend is developing a new class of oral gut-restricted […]

Eli Lilly’s tirzepatide, a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 receptor agonist (GLP-1RA), recently demonstrated that it was able to not only reduce HbA1c levels in type 2 diabetes (T2D) patients, but also confer weight loss when compared to insulin glargine in the SURPASS-4 trial. Tirzepatide has the potential to achieve […]

Research published in Nature Communications by a team from Lund University in Sweden has discovered that in Type 2 diabetes, a specific gene influences muscle stem cells’ ability to create new mature muscle cells. “In people with Type 2 diabetes, the VPS39 gene is significantly less active in the muscle cells than it is in […]

According to new research, two new but commonly-used diabetes drugs, one of which is also now approved for use in heart failure in people with or without diabetes, might be more effective in people with an Asian background than in people with a White background.    The study, led by the University of Glasgow, found […]